Evaluating the Episodic Future Thinking Intervention for Reducing Cigarette Consumption in Cigarette Smokers

Not Applicable

Recruiting

• Conditions: Cigarette Smoking-Related Carcinoma
• Interventions: Behavioral: Smoking Cessation Intervention (control); Behavioral: Smoking Cessation Intervention; Other: Medical Device Usage and Evaluation

• Registration Number: NCT05825001
• Lead Sponsor: Roswell Park Cancer Institute

Brief Summary

This clinical trial evaluates the effectiveness of active episodic future thinking (EFT) stimuli for reducing cigarette consumption in cigarette smokers. EFT is an innovative framing method shown to significantly activate brain regions involved in future thinking, planning, and other executive functions. Active EFT stimuli are positive events, unrelated to smoking, that participants anticipate, look forward to, and can vividly imagine happening up to 1 year in the future. Control EFT stimuli are positive past events, unrelated to smoking, that participants can vividly remember happening in the recent past. Active EFT stimuli may help reduce cigarette consumption among cigarette smokers by exposing them to personally relevant future oriented stimuli.

Detailed Description

PRIMARY OBJEECTIVE:

I. To evaluate the efficacy of episodic future thinking (EFT) for smoking cessation.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I (ACTIVE): Participants receive the active EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.

ARM II (CONTROL): Participants receive the control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.

Study Timeline

• Study First Submitted: 2023-04-11
• Study First Submitted QC: 2023-04-11
• Study First Posted: 2023-04-24
• Study Start: 2024-09-15
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-14
• Last Update Posted: 2024-10-16
• Primary Completion: 2025-09-01
• Study Completion: 2025-09-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

• Smoke >= 10 cigarettes daily

• > 32 on the Vividness of Visual Imagery Questionnaire (VVIQ)

• No regular use of other tobacco products

• In possession of a smartphone with text messaging capabilities

  • Willing to quit smoking in the next 30 days
  • Low socioeconomic status

Exclusion Criteria

• Unable or unwilling to provide verbal consent
• Unable or unwilling to provide data to the research team
• Current use of nicotine replacement therapy, bupropion, or varenicline
• Use of drugs of abuse in the past 30 days
• Living in the same household as a participant already enrolled in this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm 1 (active EFT)	Medical Device Usage and Evaluation	Participants receive the active EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
Arm II (control EFT)	Smoking Cessation Intervention (control)	Participants receive the control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
Arm II (control EFT)	Medical Device Usage and Evaluation	Participants receive the control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
Arm 1 (active EFT)	Smoking Cessation Intervention	Participants receive the active EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.

Primary Outcome Measures

Name	Time	Method
Concentration of carbon monoxide on breath	From baseline up to 30 days	Will be measured by Micro+Basic carbon monoxide monitor

Secondary Outcome Measures

Name	Time	Method
Reduction in delay discounting rate	Up to 30 days	participants will be guided to imagine the situational and sensory details for each of the stimuli until the vividness scores are ≥ 4 on a scale of 1-5 (1=very low, 5=very high).

Trial Locations

Locations (1)

Roswell Park Comprehensive Cancer Center; 🇺🇸 Buffalo, New York, United States